More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

DCAT Value Chain Insights

Last year was a strong year for the US and European biotechnology sectors, led by a resurgence in initial public offerings and other financing into the industry. But what will drive the sector going forward? A recent analysis, offered by EY, at...
DCAT Value Chain Insights

The approval of the first biosimilar in the US last month was only the beginning in the biosimilars market. Reimbursement and pricing policies are equally important. DCAT Value Chain Insights (VCI) examines how these federal and state measures may...
DCAT Value Chain Insights

The approval of Sandoz's Zarxio, a biosimilar of filgrastim, the active ingredient in Amgen's Neupogen, in early March 2015 by the US Food and Drug Administration marked the approval of the first biosimilar product in the US.  DCAT Value Chain...
DCAT Value Chain Insights

DCAT Week '15 provided key insights in the global pharmaceutical industry and supply strategies for small molecules and biologics. The education programs at DCAT Week '15, the flagship event of the Drug, Chemical & Associated Technologies...
DCAT Value Chain Insights

What are the blockbusters of the future? A recent industry analysis points to the leading contenders from late-stage or newly approved drugs. The commercial success of a drug is difficult to predict, but a recent analysis by Thomson Reuters points...